Regen BioPharma Regen BioPharma is a biotech company focused on the immunology and immunotherapy space. | ![]() Immune Pharmaceuticals Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics. | ![]() Nexomics Biosciences Nexomics Biosciences is a contract research organization offering gene-to‑structure services to the biopharmaceutical community. | CytoMed Therapeutics CytoMed Therapeutics is a company that focuses on translating its technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based immunotherapeutics for the treatment of cancers. | ||
Founding Date | Founding Date 2012 | Founding Date 2010 | Founding Date 2000 | Founding Date 2007 | Founding Date 2018 |
Type | Type Public | Type Public | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations La Mesa, US HQ | Locations New York, US HQ Jerusalem, IL | Locations HQ | Locations Rocky Hill, US HQ Mansfield, US | Locations Singapore, SG HQ Masai, MY |
Employees | Employees 1 | Employees 722% decrease | Employees 563 | Employees 1220% increase | Employees 24 |
Valuation ($) | Valuation ($) 1.9 m | Valuation ($) 1.6 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $236.6k (FY, 2025) | Revenue (est.) N/A | Revenue (est.) ₩124.6b (FY, 2023) | Revenue (est.) N/A | Revenue (est.) N/A |
Net income | Net income ($1.3m) (FY, 2025) | Net income ($17.9m) (FY, 2017) | Net income (₩33.6b) (FY, 2023) | Net income N/A | Net income N/A |

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics.
View company
Nexomics Biosciences is a contract research organization offering gene-to‑structure services to the biopharmaceutical community.
View companyCytoMed Therapeutics is a company that focuses on translating its technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based immunotherapeutics for the treatment of cancers.
View company